Claim by Pfizer for Arrow declarations in relation to its proposed launch in Europe, including the UK, of a biosimilar monoclonal antibody drug called bevacizumab, for the treatment of various cancers in combination with other drugs.
Judges:
Mr Justice Birss
Citations:
[2019] EWHC 1520 (Pat)
Links:
Jurisdiction:
England and Wales
Intellectual Property
Updated: 19 November 2022; Ref: scu.649987